No

Vaccine

Active immunization against Japanese encephalitis for persons 1 year of age and older who plan to spend 1 month or more in endemic areas in Asia, especially persons traveling during the transmission season or visiting rural areas; consider vaccination for shorter trips to epidemic areas or extensive outdoor activities in rural endemic areas; elderly (>55 years of age) individuals should be considered for vaccination, since they have increased risk of developing symptomatic illness after infection; those planning travel to or residence in endemic areas should consult the Travel Advisory Service (Central Campus) for specific advice

C

Serious adverse reaction (generalized urticaria or angioedema) to a prior dose of this vaccine; proven or suspected hypersensitivity to proteins or rodent or neural origin; hypersensitivity to thimerosal (used as a preservative). CDC recommends that the following should not generally receive the vaccine, unless benefit to the individual clearly outweighs the risk:

• persons with heart, kidney, or liver disorders
• persons with generalized malignancies such as leukemia or lymphoma
• persons with a history of multiple allergies or hypersensitivity to components of the vaccine
• pregnant women, unless there is a very high risk of Japanese encephalitis during the woman's stay in Asia

Severe adverse reactions manifesting as generalized urticaria or angioedema may occur within minutes following vaccination, or up to 17 days later; most reactions occur within 10 days, with the majority within 48 hours; observe vaccinees for 30 minutes after vaccination; warn them of the possibility of delayed generalized urticaria and to remain where medical care is readily available for 10 days following any dose of the vaccine; because of the potential for severe adverse reactions, Japanese encephalitis vaccine is not recommended for all persons traveling to or residing in Asia; safety and efficacy in infants <1 year of age have not been established; therefore, immunization of infants should be deferred whenever possible; it is not known whether the vaccine is excreted in breast milk

Report allergic or unusual adverse reactions to the Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967.

Simultaneous administration of DTP vaccine and Japanese encephalitis vaccine does not compromise the immunogenicity of either vaccine; data on administration with other vaccines, chloroquine, or mefloquine are lacking

Refrigerate, discard 8 hours after reconstitution

U.S. recommended primary immunization schedule:

Children 1-3 years: S.C.: Three 0.5 mL doses given on days 0, 7, and 30; abbreviated schedules should be used only when necessary due to time constraints

Booster dose: Give after 2 years, or according to current recommendation

Note: Travel should not commence for at least 10 days after the last dose of vaccine, to allow adequate antibody formation and recognition of any delayed adverse reaction

Advise concurrent use of other means to reduce the risk of mosquito exposure when possible, including bed nets, insect repellents, protective clothing, avoidance of travel in endemic areas, and avoidance of outdoor activity during twilight and evening periods

The single-dose vial should only be reconstituted with the full 1.3 mL of diluent supplied; administer 1 mL of the resulting liquid as one standard adult dose; discard the unused portion

No information available to require special precautions

No effects or complications reported

Adverse reactions may occur shortly after vaccination or up to 17 days (usually within 10 days) after vaccination

Adverse reactions may occur shortly after vaccination or up to 17 days (usually within 10 days) after vaccination

Powder for injection, lyophilized: 1 mL, 10 mL